GMED vs GKOS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 20, 2026

GMED

47.6
AI Score
VS
GKOS Wins

GKOS

57.5
AI Score

Investment Advisor Scores

GMED

48score
Recommendation
HOLD

GKOS

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED GKOS Winner
Revenue 1.55B 336.18M GMED
Net Income 275.87M -38.16M GMED
Net Margin 17.8% -11.4% GMED
Operating Income 332.82M -37.12M GMED
ROE 5.8% -5.6% GMED
ROA 5.0% -4.1% GMED
Total Assets 5.49B 920.52M GMED
Cash 507.75M 114.48M GMED
Current Ratio 4.62 5.04 GKOS
Free Cash Flow 339.32M -4.40M GMED

Relative Price Performance (Last 90 Days)

GMED 1M: +9.7% · 3M: +4.1% GKOS 1M: +15.6% · 3M: +17.9%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 63.3 · Price: $81.47

GKOS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 62.9 · Price: $179.06

Fundamentals Snapshot

Metric GMED GKOS
Market Cap — —
Forward P/E 15.2 338.0
Trailing P/E 20.2 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.5%
Gross Margin 0.7% 0.8%
Operating Margin 0.2% -0.1%
EPS 3.90 -3.26
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GKOS is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.